In the latest quarter, 4 analysts provided ratings for Harpoon Therapeutics (NASDAQ:HARP), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $17.75, along with a high estimate of $23.00 and a low estimate of $12.00. Observing a 1.43% increase, the current average has risen from the previous average price target of $17.5…